"
"
Key findings
Doctors use a diverse range of treatments for moderate
to severe dry eye or meibomian gland disease, including
artificial tears, cyclosporine, lifitegrast, oral omega-3,
thermal lid expression, punctal occlusion, corticosteroid,
topical azithromycin, and oral cyclines.
It's encouraging to see that the majority
of respondents are recognizing the huge
impact that the ocular surface has on the
outcomes of cataract surgeries. I think
this is attributable to the growing number
of refractive cataract surgery options,
better lens technologies, plus the better
therapeutic and diagnostic options for dry
eye disease management. This growing
awareness should optimistically
translate to more surgeons identifying
and treating the ocular surface around
the time of cataract surgery.
Elizabeth Yeu, MD, advisor,
Young Eye Surgeons Clinical Committee
Ocular surface/cornea
9 • 2017 ASCRS Clinical Survey
